Bangalore: Shasun pharmaceuticals, an Indian pharmaceutical company aims to focus on formulations manufacturing and marketing in the regulated markets to become a global integrated sector in the next two years. The concern expects the formulations shares to grow around 25 percent by 2016-2017.

The company plans to set up its market subsidiary in the US during the current fiscal year. The company has been a manufacturer and supplier of active pharmaceutical ingredients (API) and a contract research and manufacturing services (CRAMS) provider.

Mr S Abhay Kumar, managing director, Shasun Pharma said, "The focus is on formulations and launching formulations with API integration from our own production." Mr Abhay Kumar expects the transformation to be completed in the next two years. He also opined that the company is working to get regulatory approvals in the lucrative Japanese market for its formulations where it already has an API base.

The pharmaceutical company also plans to expand its formulations base by increasing its capacity of production and manufacturing sites.